AB-BIOTICS will showcase probiotic solutions for women’s health at Vitafoods Europe 2024

AB-BIOTICS, a Kaneka company, will exhibit at this year’s Vitafoods Europe to showcase scientific findings on its latest probiotic solutions for women’s health and sports nutrition. The company’s R&D manager, Dr Marta Pérez, will deliver a session at the Biotics Theatre, K232, on 15 May, on the role probiotics can play in managing symptoms of menopause and how AB-BIOTICS translates this into today’s offerings.

Shining a spotlight on an in-demand and under-researched therapeutic area in women’s health, AB-BIOTICS will highlight the latest research on its solution for managing menopause symptoms, commercially known as Gyntima^® Menopause. Containing a blend of strains L. plantarum KABP™ 051, L. brevis KABP™ 052 and P. acidilactici KABP™ 021, the probiotic blend provides women with a safe and effective solution for managing all stages of menopause by modulating estrogen levels in the gut.¹

The hormonal fluctuations which occur during menopause have been known to affect women’s physical and mental health. In the session titled ‘Understanding Menopause’, Dr Marta Pérez will discuss AB-BIOTICS’ clinical trial which investigated the mechanism of action and capacity of a proprietary probiotic blend to modulate serum estrogen levels.

At the event, experts from AB-BIOTICS will also discuss the relevant clinical research surrounding Gyntima^® - the company’s women’s health portfolio. This includes Gyntima^® Cyscare, for protecting the urinary tract from infections, and Gyntima® Balance, for the restoration of vaginal microbiota. Gyntima® Re-Balance, a medical device targeting vaginal infections such as candidiasis and bacterial vaginosis, will also be on display this year.

Probiotics for elite athletes

Alongside its solutions for women’s health, AB-BIOTICS will showcase the preliminary results of the latest clinical trial on its i3.1 product which shows potential to support elite athletes affected by digestive issues that often occur from undertaking high-intensity sport. The probiotic i3.1, containing strains L. plantarum KABP^TM 022, L. plantarum KABP^TM 023 and P. acidilactici KABP^TM 021, has been shown to reduce digestive complaints associated with intense physical exercise​ and could facilitate the recovery of gastrointestinal function post-exercise.²

Attendees will also hear about the findings of a recently-published study focused on probiotics for cardiovascular health. ³  L. plantarum strains KABP™ 011, KABP™ 012 and KABP™ 013, marketed as AB-LIFE®, have been shown to lower cholesterol by impacting low-density lipoprotein (LDL) particle size and apoliproteins – relevant biomarkers in atherosclerosis⁴.

AB-BIOTICS experts will also discuss recent studies for AB-KOLICARE® (B. longum KABP™ 042 CECT 7894 and P. pentosaceus KABP™ 041 CECT 8330), specially developed to target colic and gut maturation in infants, AB21® (L. plantarum KABP™ 033 CECT 3029, L. plantarum KABP™ 022 CECT 7484, L. plantarum KABP™ 023 CECT 7485, P. acidilactici KABP™ 021 CECT 7483) for the prevention of viral respiratory infections as well as AB-DIGEST (B. longum KABP™ 042 CECT 7894, P. pentosaceus KABP™ 041 CECT 8330, L. rhamnosus GG ATCC 53103) targeting dysbiosis associated with antibiotic treatments.

-----

^[1] Honda et al (submitted). Supplementation with a probiotic formula having β-glucuronidase activity modulates serum estrogen levels in healthy peri- and postmenopausal women.

^[2] AB-BIOTICS unpublished study 2024

^[3] Padro T, de Santisteban V, Huedo P, et al. Lactiplantibacillus plantarum strains KABP011, KABP012 and KABP013 modulate bile acids and cholesterol metabolism in humans. Cardiovasc Res

^[4] Kerlikowsky et al. Distinct Microbial Taxa Are Associated with LDL-Cholesterol Reduction after 12 Weeks of Lactobacillus plantarum Intake in Mild Hypercholesterolemia: Results of a Randomized Controlled Study. Probiotics and Antimicrobial Proteins, 2023.